Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Percutaneous RF ablation for lung cancer among new NICE consultations

This article was originally published in Clinica

Executive Summary

The UK’s National Institute for Health and Clinical Excellence (NICE) yesterday launched consultations on the use of the following technologies in the NHS, under its Interventional Procedures Programme: percutaneous closure of patent foramen ovale (PFO) for recurrent migraine and for the secondary prevention of recurrent paradoxical embolism in all patients and, specifically, in divers; percutaneous radiofrequency ablation for primary and secondary lung cancers; and low-intensity pulsed ultrasound for the promotion of fracture healing. The deadline for comments for this round of procedures is 24 August 2010.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel